Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Table 2 Overall results of the multivariate analysis

Endpoint	bALP		NTx		bCTx		PINP
Endpoint	P	r	P	r	P	r	P	r
BMD spine	0.6	0.16	0.06	−0.59	0.9	0.0	1.0	0.00
BMD hip	0.5	0.40	0.3	−0.83	0.9	0.0	0.8	−0.13
BMD femur	0.01	−0.87	0.4	−0.29	0.6	−0.3	1.0	−1.00
Non-vertebral fractures	0.2	−0.41	0.02	0.98	1.0	−1.0
Vertebral fractures	0.6	−0.18	0.5	0.29
Femur fractures					1.0	−1.0
Hip fractures					1.0	−1.0
Adverse events	0.08	−0.65	0.5	−0.44	0.9	0.0	0.3	−0.58
Serious adverse events			0.5	0.68	0.7	−0.3
Therapy discontinuation	0.2	−0.46	0.04	−0.60	0.4	−0.4	0.5	−0.55
Gastrointestinal adverse events	0.5	−0.40	0.8	−0.25	0.2	−0.9	0.2	−0.97
Musculoskeletal adverse events	0.1	−0.99			0.9	0.0	0.8	−0.15
Mortality					1.00	−1.0

ISSN: 1749-799X